Patents Assigned to GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT
-
Publication number: 20140134207Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: ApplicationFiled: January 24, 2014Publication date: May 15, 2014Applicant: The Government of the United States of America as represented by the Secretary of the Dept. of HeInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Publication number: 20130323243Abstract: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.Type: ApplicationFiled: October 28, 2011Publication date: December 5, 2013Applicants: US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, The Government of the United States of America as Represented by the Secretary of The Dept of HHSInventors: Gerardo Kaplan, Krishnamurthy Konduru, Jerome Jacques, Sina Bavari, Steven Bradfute
-
Publication number: 20130267029Abstract: This invention provides methods and compositions for increasing the efficiency of obtaining pluripotent stem cells, the method comprising expressing a 133p53 in cells that are being re-programmed to obtain pluripotent cells. The invention also provides method of inhibiting the proliferation of cancer stem cells, the method comprising suppressing expression of 133p53 in the cells.Type: ApplicationFiled: September 30, 2011Publication date: October 10, 2013Applicants: Fundacion Centro Nacional de Ivestigaciones Oncologicas, Carlos, The Government of the United States of America as Represented by the Secretary of The Dept. of HealtInventors: Curtis C. Harris, Izumi Horikawa, Kaori Fujita, Abdul M. Mondal, Kye-Yoon Park, Sharon R. Pine, Manuel Serrano
-
Publication number: 20130197025Abstract: The claimed subject matter relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions including the same and therapeutic methods including administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to claimed subject matter are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. Also provided are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicants: Universiteit Leiden, The Government Of The United State Of America, Represented By The Secretary, Dept. Of Health andInventors: Anikó GÖBLYÖS, Johannes BRUSSEE, Adriaan P. IJZERMAN, Zhan-Guo GAO, Kenneth JACOBSON
-
Publication number: 20110287056Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.Type: ApplicationFiled: September 13, 2007Publication date: November 24, 2011Applicants: The Government of the United States of America as represented by the Secretary of the Dept of the HH, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Hua Gu, Richard Hodes, Jeffrey J. Chiang, Ihnkyung Jang
-
Publication number: 20110281907Abstract: Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided.Type: ApplicationFiled: March 31, 2009Publication date: November 17, 2011Applicant: The Government of the United States of America, as represented by the Secretary, Dept.of Health and.Inventors: Donald P. Bottaro, Megan Peach, Marc Nicklaus, Nelly Tan
-
Publication number: 20110189209Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: ApplicationFiled: August 1, 2008Publication date: August 4, 2011Applicant: The Government of The United States of America as Represented by the Secretary, Dept. of HealthInventors: David M. Neville, JR., Jung-Hee Woo, Arthur Frankel
-
Publication number: 20110151436Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: June 23, 2011Applicant: The Government of the United States of America as represented by the Secretary, Dept. of HealthInventors: Hana Golding, Surender Khurana
-
Publication number: 20100281974Abstract: A handle assembly mounted to a dynamometer measuring device including a base mounted to an input location of the measuring device. A plurality of arms extend in a lineal direction from the base and are arranged in spaced and gap defining fashion. The arms deflect inward relative to one another upon being exerted by a compressing force and concurrent with outputting a signal through at least one strain gauge wire extending from an interior of each arm to the measuring device.Type: ApplicationFiled: May 4, 2010Publication date: November 11, 2010Applicant: The Government of the United States of America as represented by the the Secretary of the Dept. of HInventors: Bryan Wimer, Daniel E. Welcome, Christopher Warren, Thomas W. McDowell, Ren G. Dong
-
Publication number: 20100255507Abstract: The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.Type: ApplicationFiled: October 10, 2008Publication date: October 7, 2010Applicant: The Government of the United States of America, as represented by the Secretary, Dept. of HealthInventors: Eric O. Long, Sumati Rajagopalan
-
Publication number: 20100189645Abstract: Metal chelators of Formula I and Formula II are disclosed: or a pharmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.Type: ApplicationFiled: April 1, 2010Publication date: July 29, 2010Applicant: The Government of the United States of America, as represented by the Secretary, Dept. of Homeland aInventors: Martin Wade Brechbiel, Thomas Clifford
-
Publication number: 20100074916Abstract: H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines.Type: ApplicationFiled: October 10, 2007Publication date: March 25, 2010Applicant: Government of the United States of America, as represented by the Secretary, Dept. of Health andInventors: Gary J. Nabel, Zhi-yong Yang, Chih-jen Wei, Wing-pui Kong, Lan Wu
-
Publication number: 20090325156Abstract: The invention provides methods and materials for screening for polymorphic variants in ABCB1 and diagnosing altered susceptibilities for drug-induced heart rhythm irregularities based on the same. These methods allow better treatment regimens for using drugs that bind a protein encoded by the ABCB1 and/or induce heart rhythm irregularities such as the anti-cancer drug FK228.Type: ApplicationFiled: November 9, 2006Publication date: December 31, 2009Applicant: Government of the United States of America, as Represented by Secretary, Dept. of Human ServicesInventors: William D. Figg, Alexander Sparreboom, Tristan Sissung, Richard L. Piekarz, Susan E. Bates
-
Publication number: 20090208534Abstract: The invention relates to an attenuated Salmonella sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated Salmonella sp. to a patient having a solid tumor cancer, wherein said attenuated Salmonella sp. is a tumor targeting attenuated Salmonella sp. expressing a short hairpin (sh) RNA which attenuated Salmonella sp. is capable of inhibiting the growth or reducing the volume of the solid tumor cancer when administered in vivo.Type: ApplicationFiled: July 24, 2007Publication date: August 20, 2009Applicant: The Government of The United States of America, as represented by the Secretary, Dept.of HealthInventors: Deqi Xu, Dennis J. Kopecko, Jiadi Hu, Ling Zhang, Xuejian Zhao, Lifang Gao
-
Publication number: 20090088331Abstract: The present invention relates generally to methods of detecting and identifying known and unknown viruses using hybridization microarrays to essentially all known influenza virus nucleotide sequences of at least one type that infect at least one species, the sequencing of nucleotides which hybridize to the microarrays and analysis of the hybridized sequences with existing databases, thus identifying existing or new subtypes of viruses. The present invention also relates to methods of use of the microarrays of the invention for the detection of influenza viruses, including variant influenza viruses. The method includes the use of a non-specific PCR amplification method to amplify sample nucleic acids.Type: ApplicationFiled: November 7, 2007Publication date: April 2, 2009Applicant: Government of the United States of America, as represented by the Secretary, Dept. of Health andInventors: Xiaolin Wu, Cassio S. Baptista, David J. Munroe
-
Publication number: 20090010953Abstract: Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.Type: ApplicationFiled: August 21, 2008Publication date: January 8, 2009Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT.Inventors: Patrick Hwu, Rejean LaPointe, Steven A. Rosenberg, Maria Parkhurst
-
Publication number: 20080292647Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: ApplicationFiled: October 31, 2007Publication date: November 27, 2008Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT.Inventors: Yutaka Kawakami, Steven A. Rosenberg
-
Publication number: 20080289055Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: ApplicationFiled: October 31, 2007Publication date: November 20, 2008Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT.Inventors: Yutaka Kawakami, Steven A. Rosenberg
-
Publication number: 20080286804Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: ApplicationFiled: October 31, 2007Publication date: November 20, 2008Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT.Inventors: Yutaka Kawakami, Steven A. Rosenberg
-
Publication number: 20080275108Abstract: The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention.Type: ApplicationFiled: May 15, 2008Publication date: November 6, 2008Applicant: Government of the United States of America, as Represented by the Secretary, Dept. of Health andInventor: Michael R. Boyd